GlassScriptPhysician profile
Jitendra M Patel
NPI 1639260680
$7,859.30
in general payments reported to CMS, 2019-2025
42 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $883 · 2021: $901 · 2022: $1,641 · 2023: $1,415 · 2024: $1,455 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,279.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $869.04 | 2019-2025 | |
| Abbvie INC. | $859.58 | 2021-2025 | |
| Novo Nordisk INC | $611.53 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.33 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $540.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $282.03 | 2022-2025 | Xarelto, Spravato |
| Amarin Pharma, INC. | $275.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $256.62 | 2020-2025 | |
| Amgen INC. | $225.69 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $219.11 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $208.26 | 2022 | |
| Abbott Laboratories | $178.24 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $160.64 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $113.95 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.